Bisphosphonates are the mainstay of osteoporosis therapy. Extensive clinical evaluation supports their utility in stemming progression of the disease and in reducing fracture risk. In the course ...

Incyte is preparing to take an oral JAK inhibitor into phase 3 trials for the skin depigmentation disease vitiligo, after reporting mid-stage data showing efficacy in patients with facial and full ...

Vitiligo is an autoimmune skin disorder affecting about 1 in 100 people. It is characterized by a loss of pigment (coloring) in skin patches that appear white. Melanin is the natural pigment that ...